Concomitant Diabetes Mellitus and Heart Failure

Current Problems in Cardiology

Volumn 40, Issue 1, 2015, Pages 7-43

  Dei Cas, Alessandra ^a   Fonarow, Gregg C ^a   Gheorghiade, Mihai ^a   Butler, Javed ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADVANCED GLYCATION END PRODUCT; ALISKIREN; ALOGLIPTIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CARVEDILOL; DAPAGLIFLOZIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DIURETIC AGENT; EPLERENONE; EXENDIN 4; FATTY ACID; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; INSULIN; INSULIN GLARGINE; LISINOPRIL; METFORMIN; METOPROLOL; MINERALOCORTICOID ANTAGONIST; PIOGLITAZONE; PLACEBO; PROTEIN KINASE C; SAXAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA DERIVATIVE; UNINDEXED DRUG; VALSARTAN; CARDIOVASCULAR AGENT;

ACUTE CORONARY SYNDROME; ARTICLE; AUTONOMIC NEUROPATHY; BODY WEIGHT DISORDER; CALCIUM HOMEOSTASIS; CEREBROVASCULAR ACCIDENT; COMORBIDITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DIASTOLIC DYSFUNCTION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG MEGADOSE; EXERCISE TEST; FLUID RETENTION; GLYCEMIC CONTROL; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART INFARCTION; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPOGLYCEMIA; HYPOTENSION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; KIDNEY DYSFUNCTION; LACTIC ACIDOSIS; MICROANGIOPATHY; MORTALITY; NITRATIVE STRESS; NITROSATIVE STRESS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PERIPHERAL EDEMA; PREVALENCE; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SCREENING; SYSTOLIC DYSFUNCTION; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; DIABETES COMPLICATIONS; DIABETIC CARDIOMYOPATHIES; DISEASE COURSE; PATHOPHYSIOLOGY; PHENOTYPE;

CARDIOVASCULAR AGENTS; COMORBIDITY; DIABETES COMPLICATIONS; DIABETIC CARDIOMYOPATHIES; DISEASE PROGRESSION; HEART FAILURE; HUMANS; PHENOTYPE; PREVALENCE; PROGNOSIS;

EID: 84920608326     PISSN: 01462806     EISSN: 15356280     Source Type: Journal    
DOI: 10.1016/j.cpcardiol.2014.09.002     Document Type: Article

References (179)

1. Nieminen M.S., Brutsaert D., Dickstein K., et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 2006, 27:2725-2736.
2. Bertoni A.G., Hundley W.G., Massing M.W., Bonds D.E., Burke G.L., Goff D.C. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 2004, 27:699-703.
3. Sarma S., Mentz R.J., Kwasny M.J., et al. Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial. Eur J Heart Fail 2013, 15:194-202.
4. Parving H.H., Brenner B.M., McMurray J.J., et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012, 367:2204-2213.
5. Gheorghiade M., Böhm M., Greene S.J., et al. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. J Am Med Assoc 2013, 309:1125-1135.
6. Scirica B.M., Bhatt D.L., Braunwald E., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013, 369:1317-1326.
7. Monami M., Dicembrini I., Mannucci E. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2014, 24:689-697.
8. Thrainsdottir I.S., Aspelund T., Thorgeirsson G., et al. The association between glucose abnormalities and heart failure in the population-based Reykjavik study. Diabetes Care 2005, 28:612-616.
9. National Heart Lung and Blood Institute. People Science Health. What is heart failure? 〈〉 Accessed February 2012. http://www.nhlbi.nih.gov/health/health-topics/topics/hf/.
10. King H., Aubert R.E., Herman W.H. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998, 21:1414-1431.
11. Wild S., Roglic G., Green A., Sicree R., King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
12. Bonow R.O., Gheorghiade M. The diabetes epidemic: a national and global crisis. Am J Med 2004, 116(suppl 5A):2S-10S.
13. Davies M., Hobbs F., Davis R., et al. Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study. Lancet 2001, 358:439-444.
14. Hall MJ, DeFrances CJ, Williams SN, Golosinskiy A, Schwartzman A. National Hospital Discharge Survey: 2007 summary. National health statistics reports; no 29. Hyattsville, MD: National Center for Health Statistics. 〈〉 2010. http://www.cdc.gov/nchs/data/nhsr/nhsr029.pdf.
15. MacDonald M.R., Petrie M.C., Varyani F., et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 2008, 29:1377-1385.
16. De Groote P., Lamblin N., Mouquet F., et al. Impact of diabetes mellitus on long-term survival in patients with congestive heart failure. Eur Heart J 2004, 25:656-662.
17. The CONSENSUS trial study group Effect of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987, 316:1429-1435.
18. From A.M., Leibson C.L., Bursi F., Redfield M.M., Weston S.A., Jacobsen S.J., et al. Diabetes in heart failure: prevalence and impact on outcome in the population. Am J Med 2006, 119:591-599.
19. Shindler D.M., Kostis J.B., Yusuf S., et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol 1996, 77:1017-1020.
20. Cleland J.G., Swedberg K., Follath F., et al. The EuroHeart Failure survey programme-a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003, 24:442-446.
21. Adams K.F., Fonarow G.C., Emerman C.L., et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005, 149:209-216.
22. Braunstein J.B., Anderson G.F., Gerstenblith G., et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol 2003, 42:1226-1233.
23. Greenberg B.H., Abraham W.T., Albert N.M., Chiswell K., Clare R., Stough W.G., et al. Influence of diabetes on characteristics and outcomes in patients hospitalized with heart failure: a report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J 2007, 154. 277.e1-e8.
24. Nichols G.A., Gullion C.M., Koro C.E., Ephross S.A., Brown J.B. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 2004, 27:1879-1884.
25. Kannel W.B., Hjortland M., Castelli W.P. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974, 34:29-34.
26. Amato L., Paolisso G., Cacciatore F., et al. Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. The Osservatorio Geriatrico Regione Campania Group. Diabetes Metab 1997, 23:213-218.
27. Boudina S., Abel E.D. Diabetic cardiomyopathy revisited. Circulation 2007, 115:3213-3223.
28. Haffner S.M., Lehto S., Rönnemaa T., Pyörälä K., Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229-234.
29. Stamler J., Vaccaro O., Neaton J.D., Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993, 16:434-444.
30. Norhammar A., Malmberg K., Diderholm E., et al. Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. J Am Coll Cardiol 2004, 43:585-591.
31. UK Prospective Diabetes Study Group UK prospective diabetes study 16: overview of 6 years of therapy of type II diabetes: a progressive disease. Diabetes 1995, 44:1249-1258.
32. Zavaroni I., Bonini L., Gasparini P., et al. Hyperinsulinemia in a normal population as a predictor of non-insulin-dependent diabetes mellitus, hypertension, and coronary heart disease: the Barilla factory revisited. Metab Clin Exp 1994, 48:989-994.
33. Moreno P.R., Murcia A.M., Palacios I.F., et al. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation 2000, 102:2180-2184.
34. Silva J.A., Escobar A., Collins T.J., Ramee S.R., White C.J. Unstable angina: a comparison of angioscopic findings between diabetic and nondiabetic patients. Circulation 1995, 92:1731-1736.
35. Murcia A.M., Hennekens C.H., Lamas G.A., et al. Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction. Arch Intern Med 2004, 164:2273-2279.
36. Karason K., Sjöström L., Wallentin I., Peltonen M. Impact of blood pressure and insulin on the relationship between body fat and left ventricular structure. Eur Heart J 2003, 24:1500-1505.
37. Dei Cas A., Spigoni V., Ridolfi V., Metra M. Diabetes and chronic heart failure: from diabetic cardiomyopathy to therapeutic approach. Endocr Metab Immune Disord Drug Targets 2013, 13:38-50.
38. Herrero P., Peterson L.R., McGill J.B., Matthew S., Lesniak D., Dence C. Increased myocardial fatty acid metabolism in patients with type 1 diabetes mellitus. J Am Coll Cardiol 2006, 47:598-604.
39. Buchanan J., Mazumder P.K., Hu P., et al. Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology 2005, 146:5341-5349.
40. Peterson L.R., Herrero P., Schechtman K.B., et al. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation 2004, 109:2191-2196.
41. Sharma S., Adrogue J.V., Golfman L., et al. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J 2004, 18:1692-1700.
42. Wang C.N., O'Brien L., Brindley D.N. Effects of cell-permeable ceramides and tumor necrosis factor-alpha on insulin signaling and glucose uptake in 3T3-L1 adipocytes. Diabetes 1998, 47:24-31.
43. Marcovina S.M., Sirtori C., Peracino A., et al. Translating the basic knowledge of mitochondrial functions to metabolic therapy: role of l-carnitine. Transl Res 2013, 161:73-84.
44. Boudina S., Abel E.D. Mitochondrial uncoupling: a key contributor to reduced cardiac efficiency in diabetes. Physiology (Bethesda) 2006, 21:250-258.
45. Boudina S., Sena S., O'Neill B.T., Tathireddy P., Young M.E., Abel E.D. Reduced mitochondrial oxidative capacity and increased mitochondrial uncoupling impair myocardial energetics in obesity. Circulation 2005, 112:2686-2695.
46. Shen X., Zheng S., Thongboonkerd V., et al. Cardiac mitochondrial damage and biogenesis in a chronic model of type 1 diabetes. Am J Physiol Endocrinol Metab 2004, 287:E896-E905.
47. Metzler B., Schocke M.F., Steinboeck P., et al. Decreased high-energy phosphate ratios in the myocardium of men with diabetes mellitus type I. J Cardiovasc Magn Reson 2002, 4:493-502.
48. Anderson E.J., Kypson A.P., Rodriguez E., Anderson C.A., Lehr E.J., Neufer P.D. Substrate-specific derangements in mitochondrial metabolism and redox balance in the atrium of the type 2 diabetic human heart. J Am Coll Cardiol 2009, 54:1891-1898.
49. Rupp H., Elimban V., Dhalla N.S. Modification of myosin isozymes and SR Ca(2+)-pump ATPase of the diabetic rat heart by lipid-lowering interventions. Mol Cell Biochem 1994, 132:69-80.
50. Malhotra A., Sanghi V. Regulation of contractile proteins in diabetic heart. Cardiovasc Res 1997, 34:34-40.
51. Trost S.U., Belke D.D., Bluhm W.F., Meyer M., Swanson E., Dillmann W.H. Overexpression of the sarcoplasmic reticulum Ca(2)-ATPase improves myocardial contractility in diabetic cardiomyopathy. Diabetes 2002, 51:1166-1171.
52. Xu J., Zhou Q., Xu W., Cai L. Endoplasmic reticulum stress and diabetic cardiomyopathy. Exp Diabetes Res 2012, 2012:827-871.
53. Fang Z.Y., Prins J.B., Marwick T.H. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev 2004, 25:543-567.
54. Hartog J.W., Voors A.A., Bakker S.J., Smit A.J., van Veldhuisen D.J. Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications. Eur J Heart Fail 2007, 9:1146-1155.
55. Bierhaus A., Hofmann M.A., Ziegler R., Nawroth P.P. The AGE/RAGE pathway in vascular disease and diabetes mellitus. Part I. The AGE-concept. Cardiovasc Res 1998, 37:586-600.
56. Bierhaus A., Schiekofer S., Schwaninger M., et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 2001, 50:2792-2808.
57. Way K.J., Isshiki K., Suzuma K., et al. Expression of connective tissue growth factor is increased in injured myocardium associated with protein kinase C beta2 activation and diabetes. Diabetes 2002, 51:2709-2718.
58. Connelly K.A., Kelly D.J., Zhang Y., et al. Inhibition of protein kinase C-beta by ruboxistaurin preserves cardiac function and reduces extracellular matrix production in diabetic cardiomyopathy. Circ Heart Fail 2009, 2:129-137.
59. He Z., Way K.J., Arikawa E., et al. Differential regulation of angiotensin II-induced expression of connective tissue growth factor by protein kinase C isoforms in the myocardium. J Biol Chem 2005, 280:15719-15726.
60. Fiordaliso F., Cuccovillo I., Bianchi R., et al. Cardiovascular oxidative stress is reduced by an ACE inhibitor in a rat model of streptozotocin-induced diabetes. Life Sci 2006, 79:121-129.
61. Liu X., Suzuki H., Sethi R., Tappia P.S., Takeda N., Dhalla N.S. Blockade of the renin-angiotensin system attenuates sarcolemma and sarcoplasmic reticulum remodeling in chronic diabetes. Ann N Y Acad Sci 2006, 1084:141-154.
62. Pacher P., Szabó C. Role of peroxynitrite in the pathogenesis of cardiovascular complications of diabetes. Curr Opin Pharmacol 2006, 6:136-141.
63. Pacher P., Liaudet L., Soriano F.G., Mabley J.G., Szabó E., Szabó C. The role of poly(ADP-ribose) polymerase in the development of myocardial and endothelial dysfunction in diabetes mellitus. Diabetes 2002, 51:514-521.
64. Adameova A., Dhalla N.S. Role of microangiopathy in diabetic cardiomyopathy. Heart Fail Rev 2014, 19:25-33.
65. Marti C.N., Gheorghiade M., Kalogeropoulos A.P., Georgiopoulou V.V., Quyyumi A.A., Butler J. Endothelial dysfunction, arterial stiffness, and heart failure. J Am Coll Cardiol 2012, 60:1455-1469.
66. Strauer B.E., Motz W., Vogt M., Schwartzkopff B. Impaired coronary flow reserve in NIDDM: a possible role for diabetic cardiopathy in humans. Diabetes 1997, 46:S119-S124.
67. Ziegler D. Diagnosis and treatment of diabetic autonomic neuropathy. Curr Diab Rep 2001, 1:216-227.
68. DCCT The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). Diabetologia 1998, 41:416-423.
69. Axelrod S., Lishner M., Oz O., Bernheim J., Ravid M. Spectral analysis of fluctuations in heart rate: an objective evaluation of autonomic nervous control in chronic renal failure. Nephron 1987, 45:202-206.
70. Drake-Holland A.J., Van der Vusse G.J., Roemen T.H., et al. Chronic catecholamine depletion switches myocardium from carbohydrate to lipid utilisation. Cardiovasc Drugs Ther 2001, 15:111-117.
71. Schrauwen P., Hoeks J., Hesselink M.K. Putative function and physiological relevance of the mitochondrial uncoupling protein-3: involvement in fatty acid metabolism?. Prog Lipid Res 2006, 45:17-41.
72. Rathmann W., Ziegler D., Jahnke M., Haastert B., Gries F.A. Mortality in diabetic patients with cardiovascular autonomic neuropathy. Diabet Med 1993, 10:820-824.
73. Pop-Busui R., Evans G.W., Gerstein H.C., et al. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care 2010, 33:1578-1584.
74. Piccini J.P., Klein L., Gheorghiade M., Bonow R.O. New insights into diastolic heart failure: role of diabetes mellitus. Am J Med 2004, 116(suppl 5A):64S-75S.
75. Boyer J.K., Thanigaraj S., Schechtman K.B., Pérez J.E. Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. Am J Cardiol 2004, 93:870-875.
76. Zabalgoitia M., Ismaeil M.F., Anderson L., Maklady F.A. Prevalence of diastolic dysfunction in normotensive, asymptomatic patients with well-controlled type 2 diabetes mellitus. Am J Cardiol 2001, 87:320-323.
77. Liu J.E., Palmieri V., Roman M.J., et al. The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: the Strong Heart Study. J Am Coll Cardiol 2001, 37:1943-1949.
78. Astorri E., Fiorina P., Contini G.A., et al. Isolated and preclinical impairment of left ventricular filling in insulin-dependent and non-insulin-dependent diabetic patients. Clin Cardiol 1997, 20:536-540.
79. Raev D.C. Which left ventricular function is impaired earlier in the evolution of diabetic cardiomyopathy? An echocardiographic study of young type I diabetic patients. Diabetes Care 1994, 17:633-639.
80. Fonseca C.G., Dissanayake A.M., Doughty R.N., et al. Three-dimensional assessment of left ventricular systolic strain in patients with type 2 diabetes mellitus, diastolic dysfunction, and normal ejection fraction. Am J Cardiol 2004, 94:1391-1395.
81. Jellis C.L., Stanton T., Leano R., Martin J., Marwick T.H. Usefulness of at rest and exercise hemodynamics to detect subclinical myocardial disease in type 2 diabetes mellitus. Am J Cardiol 2011, 107:615-621.
82. Metra M., Zacà V., Parati G., et al. Cardiovascular and noncardiovascular comorbidities in patients with chronic heart failure. J Cardiovasc Med (Hagerstown) 2011, 12:76-84.
83. Bertoni A.G., Hundley W.G., Massing M.W., Bonds D.E., Burke G.L., Goff D.C. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 2004, 27:699-703.
84. Parissis J.T., Rafouli-Stergiou P., Mebazaa A., et al. Acute heart failure in patients with diabetes mellitus: clinical characteristics and predictors of in-hospital mortality. Int J Cardiol 2012, 157:108-113.
85. Nodari S., Manerba A., Vaccari A., et al. Six-year prognosis of diabetic patients with coronary artery disease. Eur J Clin Invest 2012, 42:376-383.
86. Gustafsson I., Brendorp B., Seibaek M., et al. Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure. J Am Coll Cardiol 2004, 43:771-777.
87. Iribarren C., Karter A.J., Go A.S., et al. Glycemic control and heart failure among adult patients with diabetes. Circulation 2001, 103:2668-2673.
88. Bourassa M.G., Gurné O., Bangdiwala S.I., et al. Natural history and patterns of current practice in heart failure. J Am Coll Cardiol 1993, 22:14A-19A.
89. Bhalla M.A., Chiang A., Epshteyn V.A., et al. Prognostic role of B-type natriuretic peptide levels in patients with type 2 diabetes mellitus. J Am Coll Cardiol 2004, 44:1047-1052.
90. Fang Z.Y., Schull-Meade R., Leano R., Mottram P.M., Prins J.B., Marwick T.H. Screening for heart disease in diabetic subjects. Am Heart J 2005, 149:349-354.
91. Peng Q., Hu W., Su H., Yang Q., Cheng X. Levels of B-type natriuretic peptide in chronic heart failure patients with and without diabetes mellitus. Exp Ther Med 2013, 5:229-232.
92. Yufu K., Takahashi N., Nakagawa M., Hara M., Saikawa T., Yoshimatsu H. Brain natriuretic peptide and cardiac autonomic function in type 2 diabetic patients. Diabetes Res Clin Pract 2006, 72:12-19.
93. Maya L., Villarreal F.J. Diagnostic approaches for diabetic cardiomyopathy and myocardial fibrosis. J Mol Cell Cardiol 2010, 48:524-529.
94. Ihm S.H., Youn H.J., Shin D.I., et al. Serum carboxy-terminal propeptide of type I procollagen (PIP) is a marker of diastolic dysfunction in patients with early type 2 diabetes mellitus. Int J Cardiol 2007, 122:e36-e38.
95. Ban C., Twigg S. Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markers. Vasc Health Risk Manag 2008, 4:575-596.
96. Paulus W.J., Tschöpe C., Sanderson J.E., et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007, 28:2539-2550.
97. Hunt S.A., Abraham W.T., Chin M.H., et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009, 53:e1-e90.
98. Inzucchi S.E., Bergenstal R.M., Buse J.B., et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35:1364-1379.
99. Brunner H.R. Experimental and clinical evidence that angiotensin II is an independent risk factor for cardiovascular disease. Am J Cardiol 2001, 87:3C-9C.
100. Rajagopalan S., Duquaine D., King S., Pitt B., Patel P. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 2002, 105:2212-2216.
101. Struthers A.D. Aldosterone-induced vasculopathy: a new reversible cause of cardiac death. J Renin Angiotensin Aldosterone Syst 2001, 2:211-214.
102. The SOLVD Investigators Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991, 325:293-302.
103. Moyé L.A., Pfeffer M.A., Wun C.C. Uniformity of captopril benefit in the SAVE Study: subgroup analysis. Survival and Ventricular Enlargement Study. Eur Heart J 1994, 15(suppl B):2-8. [26-30].
104. Gustafsson I., Torp-Pedersen C., Køber L., Gustafsson F., Hildebrandt P., Trace Study Group Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction. J Am Coll Cardiol 1999, 34:83-89.
105. Borghi C., Ambrosioni E., Magnani B., The SMILE Study Investigators.Survival of Myocardial Infarction Long-term Evaluation Effects of the early administration of zofenopril on onset and progression of congestive heart failure in patients with anterior wall acute myocardial infarction. Am J Cardiol 1996, 78:317-322.
106. Ryden L., Armstrong P.W., Cleland J.G., et al. Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. Eur Heart J 2000, 21:1967-1978.
107. Carr A.A., Kowey P.R., Devereux R.B., et al. Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies. Am J Cardiol 2005, 96:1530-1536.
108. Berl T., Hunsicker L.G., Lewis J.B., et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 2003, 138:542-549.
109. Abuissa H., Jones P.G., Marso S.P., O'Keefe J.H. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 2005, 46:821-826.
110. Young J.B., Dunlap M.E., Pfeffer M.A., Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Investigators and Committees Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation 2004, 110:2618-2626.
111. Cohn J.N., Tognoni G., Valsartan Heart Failure Trial Investigators A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667-1675.
112. Juurlink D.N., Mamdani M.M., Lee D.S., et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 2004, 351:543-551.
113. Vardeny O., Wu D.H., Desai A., et al. Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). J Am Coll Cardiol 2012, 60:2082-2089.
114. Kosugi T., Heinig M., Nakayama T., Matsuo S., Nakagawa T. eNOS knockout mice with advanced diabetic nephropathy have less benefit from reninangiotensin blockade than from aldosterone receptor antagonists. Am J Pathol 2010, 176:619-629.
115. Ohtani T., Ohta M., Yamamoto K., et al. Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: beneficial effects of mineralocorticoid receptor blocker. Am J Physiol Regul Integr Comp Physiol 2007, 292:R946-R954.
116. Barnes B.J., Howard P.A. Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure. Ann Pharmacother 2005, 39:68-76.
117. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321.
118. Preiss D., van Veldhuisen D.J., Sattar N., et al. Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Eur J Heart Fail 2012, 14:909-915.
119. Jacob S., Rett K., Henriksen E.J. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents?. Am J Hypertens 1998, 11:1258-1265.
120. Gheorghiade M., Goldstein S. Beta-blockers in the post-myocardial infarction patient. Circulation 2002, 106:394-398.
121. Domanski M., Krause-Steinrauf H., Deedwania P., et al. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol 2003, 42:914-922.
122. Deedwania P.C., Giles T.D., Klibaner M., et al. Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. Am Heart J 2005, 149:159-167.
123. Packer M., Fowler M.B., Roecker E.B., et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002, 106:2194-2199.
124. Bobbio M., Ferrua S., Opasich C., et al. Survival and hospitalization in heart failure patients with or without diabetes treated with beta-blockers. J Card Fail 2003, 9:192-202.
125. Erdmann E., Lechat P., Verkenne P., Wiemann H. Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur J Heart Fail 2001, 3:469-479.
126. Shekelle P.G., Rich M.W., Morton S.C., et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003, 41:1529-1538.
127. Nodari S., Metra M., Dei Cas A., Dei Cas L. Efficacy and tolerability of the long-term administration of carvedilol in patients with chronic heart failure with and without concomitant diabetes mellitus. Eur J Heart Fail 2003, 5:803-809.
128. Packer M., Coats A.J., Fowler M.B., et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001, 344:1651-1658.
129. Torp-Pedersen C., Metra M., Charlesworth A., et al. Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). Heart 2007, 93:968-973.
130. von Bibra H., Hansen A., Dounis V., Bystedt T., Malmberg K., Rydén L. Augmented metabolic control improves myocardial diastolic function and perfusion in patients with non-insulin dependent diabetes. Heart 2004, 90:1483-1484.
131. Patel A., MacMahon S., Chalmers J., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572.
132. Sorajja P., Chareonthaitawee P., Rajagopalan N., et al. Improved survival in asymptomatic diabetic patients with high-risk SPECT imaging treated with coronary artery bypass grafting. Circulation 2005, 112:I311-I316.
133. Cryer P.E. Hypoglycemia-associated autonomic failure in diabetes. Am J Physiol Endocrinol Metab 2001, 281:E1115-E1121.
134. Ukena C., Dobre D., Mahfoud F., et al. Hypo- and hyperglycemia predict outcome in patients with left ventricular dysfunction after acute myocardial infarction: data from EPHESUS. J Card Fail 2012, 18:439-445.
135. Eurich D.T., Majumdar S.R., McAlister F.A., et al. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 2005, 28:2345-2351.
136. Eurich D.T., McAlister F.A., Blackburn D.F., et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. Br Med J 2007, 335:497.
137. MacDonald M.R., Eurich D.T., Majumdar S.R., et al. Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research Database. Diabetes Care 2010, 33:1213-1218.
138. Ouyang J., Parakhia R.A., Ochs R.S. Metformin activates AMP kinase through inhibition of AMP deaminase. J Biol Chem 2011, 286:1-11.
139. Dyck J.R., Lopaschuk G.D. AMPK alterations in cardiac physiology and pathology: enemy or ally?. J Physiol 2006, 574:95-112.
140. Shah D.D., Fonarow G.C., Horwich T.B. Metformin therapy and outcomes in patients with advanced systolic heart failure and diabetes. J Card Fail 2010, 16:200-206.
141. Masoudi F.A., Inzucchi S.E., Wang Y., Havranek E.P., Foody J.M., Krumholz H.M. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005, 111:583-590.
142. Dormandy J.A., Charbonnel B., Eckland D.J., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 2005, 366:1279-1289.
143. Horio T., Suzuki M., Suzuki K., et al. Pioglitazone improves left ventricular diastolic function in patients with essential hypertension. Am J Hypertens 2005, 18:949-957.
144. Lincoff A.M., Wolski K., Nicholls S.J., Nissen S.E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007, 298:1180-1188.
145. Giles T.D., Miller A.B., Elkayam U., Bhattacharya M., Perez A. Pioglitazone and heart failure: results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunction. J Card Fail 2008, 14:445-452.
146. Lefer D.J., Nichols C.G., Coetzee W.A. Sulfonylurea receptor 1 subunits of ATP-sensitive potassium channels and myocardial ischemia/reperfusion injury. Trends Cardiovasc Med 2009, 19:61-67.
147. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.
148. Andersson C., Gislason G.H., Jørgensen C.H., et al. Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure. Diabetes Res Clin Pract 2011, 94:119-125.
149. Tzoulaki I., Molokhia M., Curcin V., et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. Br Med J 2009, 339:b4731.
150. McAlister F.A., Eurich D.T., Majumdar S.R., Johnson J.A. The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy. Eur J Heart Fail 2008, 10:703-708.
151. Smooke S., Horwich T.B., Fonarow G.C. Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am Heart J 2005, 149:168-174.
152. Eshaghian S., Horwich T.B., Fonarow G.C. An unexpected inverse relationship between HbA1c levels and mortality in patients with diabetes and advanced systolic heart failure. Am Heart J 2006, 151:91.
153. Gerstein H.C., Bosch J., Dagenais G.R., et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012, 367:319-328.
154. Ban K., Noyan-Ashraf M.H., Hoefer J., Bolz S.S., Drucker D.J., Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008, 117:2340-2350.
155. Zhao T., Parikh P., Bhashyam S., et al. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther 2006, 317:1106-1113.
156. Noyan-Ashraf M.H., Momen M.A., Ban K., et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009, 58:975-983.
157. Liu Q., Anderson C., Broyde A., et al. Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure. Cardiovasc Diabetol 2010, 9:76.
158. Poornima I., Brown S.B., Bhashyam S., Parikh P., Bolukoglu H., Shannon R.P. Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat. Circ Heart Fail 2008, 1:153-160.
159. Vyas A.K., Yang K.C., Woo D., et al. Exenatide improves glucose homeostasis and prolongs survival in a murine model of dilated cardiomyopathy. PLoS One 2011, 6:e17178.
160. Khan M.A., Deaton C., Rutter M.K., Neyses L., Mamas M.A. Incretins as a novel therapeutic strategy in patients with diabetes and heart failure. Heart Fail Rev 2013, 18:141-148.
161. Sokos G.G., Nikolaidis L.A., Mankad S., Elahi D., Shannon R.P. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006, 12:694-699.
162. Best J.H., Hoogwerf B.J., Herman W.H., et al. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care 2011, 34:90-95.
163. Ratner R., Han J., Nicewarner D., Yushmanova I., Hoogwerf B.J., Shen L. Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol 2011, 10:22.
164. White W.B., Cannon C.P., Heller S.R., et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013, 369:1327-1335.
165. Hocher B, Reichetzeder C., Alter M.L. Renal and cardiac effects of DPP4 inhibitors-from preclinical development to clinical research. Kidney Blood Press Res 2012, 36:65-84.
166. Idris I., Donnelly R. Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug. Diabetes Obes Metab 2009, 11:79-88.
167. Ferrannini E., Ramos S.J., Salsali A., Tang W., List J.F. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010, 33:2217-2224.
168. Bayeva M., Gheorghiade M., Ardehali H. Mitochondria as a therapeutic target in heart failure. J Am Coll Cardiol 2013, 61:559-610.
169. Holubarsch C.J., Rohrbach M., Karrasch M., et al. A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study. Clin Sci (Lond) 2007, 113:205-212.
170. Lee L., Campbell R., Scheuermann-Freestone M., et al. Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation 2005, 112:3280-3288.
171. Fragasso G., Palloshi A., Puccetti P., et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol 2006, 48:992-998.
172. Kantor P.F., Lucien A., Kozak R., Lopaschuk G.D. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000, 86:580-588.
173. Zhang L., Lu Y., Jiang H., et al. Additional use of trimetazidine in patients with chronic heart failure: a meta-analysis. J Am Coll Cardiol 2012, 59:913-922.
174. Sossalla S., Maier L.S. Role of ranolazine in angina, heart failure, arrhythmias, and diabetes. Pharmacol Ther 2012, 133:311-323.
175. Chisholm J.W., Goldfine A.B., Dhalla A.K., et al. Effect of ranolazine on A1C and glucose levels in hyperglycemic patients with non-ST elevation acute coronary syndrome. Diabetes Care 2010, 33:1163-1168.
176. Kosiborod M., Arnold S.V., Spertus J.A., et al. Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). J Am Coll Cardiol 2013, 61:2038-2045.
177. + channels in pancreatic α-cells has anti-diabetic effects. Diabetes 2014, 10.2337/db13-1562.
178. Towler M.C., Hardie D.G. AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 2007, 100:328-341.
179. Arad M., Seidman C.E., Seidman J.G. AMP-activated protein kinase in the heart: role during health and disease. Circ Res 2007, 100:474-488.